• bioresorbable scaffold
• bvs
• coronary artery disease
• drug eluting stent
• percutaneous coronary intervention
• young

AIMS: to evaluate the clinical outcomes after the use of the Absorb® bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA, USA) compared with Xience® and Promus® metal everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, CA, USA; Boston Scientific, Marlborough, MA, USA), in young patients (≤ 45 years old) with acute coronary syndrome (ACS).

METHODS: a total of 129 young (≤ 45 years old) patients with acute coronary syndrome, were collected for this study. Those patients were divided in two groups: a first group of 71 all consecutive patients treated with BVS between September 2012 and September 2015 (BVS group) was compared with a second group of 58 consecutive patients treated with a Xience or Promus metal everolimus-eluting stent, between January 2009 and October 2012 (EES group), when the BVS was not already available. The primary end point was device-oriented composite end point (DOCE) including cardiac death, device thrombosis and device restenosis at two years follow-up.

RESULTS: baseline characteristics are similar between groups. Lesion characteristics were also similar between groups, except for the bifurcations lesions that were more frequent in EES group. Procedural success was obtained in all but three patients in the BVS group. At two years follow-up, no significant differences were observed in terms of DOCE (BVS 4.2% vs EES 5.2%, p > 0.05). Definite or probable in-stent/scaffold thrombosis occurred in one patient in each group.

CONCLUSIONS: BVS implantation for young patients with ACS is safe, with outcomes comparable with those of drug-eluting metal stents.